| Literature DB >> 3918502 |
Abstract
This review describes the current clinical results of phase I and II trials of new antitumor drugs such as the new anthracyclines: epirubicin, idarubicin, esorubicin, carminomycin and marcellomycin; the second generation cisplatin: carboplantin, CHIP, TNO-6, DACCP and JM-40; mitoxantrone, AMSA, AZQ, Tiazofurin, DFMO and others.Entities:
Mesh：
Substances：
Year: 1985 PMID： 3918502
Source DB: PubMed Journal: Gan To Kagaku Ryoho ISSN： 0385-0684